Photo: Echo IQ
May 1, 2026 — Echo IQ recently announced it has deployed its AI-based decision support software for the assessment of severe aortic stenosis, EchoSolv AS, with the Mount Sinai Health System in New York.
“This deployment is an important step in our US commercial growth and underscores increasing interest in solutions that can support cardiologists within routine echocardiography workflows," said Nick Lubbers, U.S. president and general manager for Echo IQ. "We believe EchoSolv AS offers a practical, measurement-based second look that can help physicians assess severe aortic stenosis more consistently and look forward to working with the Mount Sinai Health System to demonstrate its utility at scale.
Stamatios Lerakis MD, PhD*, Director of the Cardiovascular Imaging Program and Imaging for Structural and Valve Interventions for Mount Sinai Health System, said, “We are excited about the opportunity to bring EchoSolv AS into our echocardiography workflow for the evaluation of patients with aortic stenosis. This product can highlight patients with aortic stenosis that can be otherwise under-diagnosed, remain untreated and as a result, not benefit from the tremendous therapeutic advancements in the space of aortic valve diseases. I see this as an adjunct for the echocardiographer who will always have the final say on the interpretation! This product will only strengthen patient care.”
Mount Sinai Health System comprises seven hospitals, more than 400 outpatient practices and a globally recognized medical school, the Icahn School of Medicine at Mount Sinai. The system services millions of patient interactions annually, encompasses over 3,760 beds across campuses, and is consistently ranked among the top hospitals in the US across multiple specialties.
*Dr. Stamatios Lerakis serves as a paid key opinion leader, speaker and advisory board member for Echo IQ Limited.
April 14, 2026 
